TIDMAGY
Allergy Therapeutics PLC
07 May 2019
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Allergy Therapeutics Publishes New Research Exploring Potential
of its Adjuvant Systems in the Treatment of Cancer in the Journal
of ImmunoTherapy of Cancer
- Research illustrates broad, novel applications of the Group's
adjuvant systems portfolio beyond allergy indications -
7 May 2019 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, today announces, through its adjuvant research division
Bencard Adjuvant Systems, the publication of new research into the
Group's adjuvant system Microcrystalline Tyrosine (MCT(R) )
combined with Virus-Like particles (VLPs).
The research, Vaccination with nanoparticles combined with
micro-adjuvants protects against cancer (Mohsen M et al.),
undertaken by the Group's adjuvant research division, Bencard
Adjuvant Systems and published in the Journal for ImmunoTherapy of
Cancer, investigated the protective efficacy of the Group's
adjuvant system against cancer and showed that the combination of
MCT and VLPs caused tumour regression in an aggressive melanoma
mouse model and initiated a highly protective CD8 T-cell immune
response.
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics,
said: "Our strategy for growth with our adjuvant division, Bencard
Adjuvant Systems, focuses on extending the use of MCT(R) and VLPs
in developing vaccines for unmet needs and disease areas beyond
allergy that require an effective depot adjuvant. This
ground-breaking work, completed in collaboration with the Jenner
Institute at the University of Oxford, supports this strategy and
complements the existing work illustrating the potential of our
adjuvant systems in disease areas such as influenza and
malaria."
About the study: Microcrystalline Tyrosine and Virus-Like
Particles in treating cancer
The paper was published in conjunction with collaborators from
the Jenner Institute, Oxford, UK and University of Bern,
Switzerland and describes how the depot effect of MCT allows
release of VLP-antigen to reach lymphoid organs efficiently
(<72hrs) for optimal priming of T-cells.
The induction of strong T-cell responses, in particular
cytotoxic T-cells, is key for the generation of an efficacious
therapeutic cancer vaccine. The study showed that VLPs rapidly
drain into the lymphatic system due to their nano-size. However,
formulating the nanoparticles with the micron-sized MCT adjuvant
resulted in a local depot for the nanoparticles and a longer
exposure time for the immune system. In doing so, the MCT:VLP was
similarly potent to other commonly used adjuvants such as the
potent B type immunostimulatory CpGs and performed better than Alum
in inducing cytotoxic T lymphocytes and tumour protection.
MCT has been used in the clinic for decades in allergen-specific
desensitisation. The potential shown in this study may therefore
readily translate into a clinical setting to optimise the induction
of cytotoxic T-cells in humans to drive protection against
melanoma.
- ENDS -
Mohsen M et al., Vaccination with nanoparticles combined with
micro-adjuvants protects against cancer. J Immunotherapy of Cancer.
(2019) 7:114 Available to access here
https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0587-z
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Bencard Adjuvant Systems
Bencard Adjuvant Systems is a division of Allergy Therapeutics
UK; a fully integrated, speciality pharmaceutical company. Located
in Worthing, on England's south coast, Bencard Adjuvant Systems
specialise in developing and optimising adjuvants for infectious
diseases, cancer immunotherapy and allergen immunotherapy. Bencard
Adjuvant Systems are committed to engaging in long-term
partnerships with those who require adjuvant technologies to enable
successful vaccine or immunotherapy development.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third-party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development include vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Adjuvant systems to boost performance of vaccines outside allergy
are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
References:
Mohsen M et al., Vaccination with nanoparticles combined with
micro-adjuvants protects against cancer. J Immunotherapy of Cancer.
(2019) 7:114
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGUQAAUPBPGQ
(END) Dow Jones Newswires
May 07, 2019 02:01 ET (06:01 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024